

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alcassedan, Virginia 22313-1450 www.emplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/585,715	05/14/2007	Sergey I. Chernysh	SPSUP0100WOUS	4071
23908 7590 01/28/2009 RENNER OTTO BOISSELLE & SKLAR, LLP			EXAMINER	
1621 EUCLID AVENUE NINETEENTH FLOOR CLEVELAND, OH 44 115			GUSSOW, ANNE	
			ART UNIT	PAPER NUMBER
	,		1643	
			MAIL DATE	DELIVERY MODE
			01/28/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice to Comply

Application No.	Applicant(s)	
10585715	CHERNYSH ET AL.	
Examiner ANNE M. GUSSOW	Art Unit	

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandoment under 35 U.S.C. & 133 (extensions of time may be obtained under the provisions of 37 CER

/Anne M Gussow/ Examiner, Art Unit 1643				
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY				
For Rules Interpretation, call (571) 272-0731 or (571) 272-0951 For CRF Submission Help, call (571) 272-2510 PatentIn Software Program Support Technical Assistance.1-866-217-9197 or 703-305-3028 or 571-272-6845 PatentIn Software is Available At www.USPTO.gov				
For questions regarding compliance to these requirements, please contact:				
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).				
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.				
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".				
7. Other:				
 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). 				
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).				
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."				
 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). 				
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).				
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).				
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):				
to avoid abandonment under 35 0.5.c. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).				

U.S. Patent and Trademark Office Part of Paper No. 20090121